Actuate Therapeutics Inc (ACTU) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Actuate Therapeutics Inc (ACTU) Earnings Overview
As of June 13, 2026, Actuate Therapeutics Inc (ACTU) reported trailing twelve-month net income of -$22M, reflecting +67.5% year-over-year growth. The company earned $-0.92 per diluted share over the past four quarters.
Looking at the long-term picture, ACTU's historical earnings data spans multiple years. The company achieved its highest annual net income of -$20M in fiscal 2022.
Actuate Therapeutics Inc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), TPVG (-$12M net income, 50.6% margin), AGIO (-$423M net income, -764.0% margin), ACTU has comparable earnings metrics. Compare ACTU vs IMVT →
ACTU Earnings vs Peers
Earnings metrics vs comparable public companies
ACTU Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$22M | +18.5% | -$22M | $-1.06 | - | - |
| 2024 | -$27M | -10.3% | -$25M | $-3.26 | - | - |
| 2023 | -$25M | -22.7% | -$25M | $-1.65 | - | - |
| 2022 | -$20M | - | -$20M | $-1.34 | - | - |
Download Data
Export ACTU earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in ACTU back in 2022?
Total return with dividends reinvested · 4+ years of data
Calculate ReturnsHow much would $100/month in ACTU be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ACTU Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationACTU vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowACTU — Frequently Asked Questions
Quick answers to the most common questions about buying ACTU stock.
What is ACTU earnings per share (EPS)?
ACTU trailing twelve-month (TTM) diluted EPS is $-0.92, reflecting +67.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Actuate Therapeutics Inc's net income?
Actuate Therapeutics Inc (ACTU) trailing twelve-month net income is $-22M as of 2025. Earnings grew +67.5% year-over-year.
Is ACTU profitable?
ACTU is not currently profitable on a TTM basis, reporting a net loss of $-22M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ACTU's earnings growth rate?
ACTU compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are ACTU's profit margins?
Actuate Therapeutics Inc net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -553.7%.
Is ACTU growing earnings?
Yes, ACTU earnings are accelerating — EPS growth of +67.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-22M. Earnings momentum is strengthening.
What was ACTU's best earnings year?
Actuate Therapeutics Inc's highest annual net income on record is $-20M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were ACTU's earnings last quarter?
ACTU's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.24. For a full breakdown of all quarters, see the quarterly earnings table on this page.